文献速递心力衰竭与心肌病

NT-proBNP长期变化与心衰及死亡风险的关联

Association of Long-term Change in N-Terminal Pro-B-Type Natriuretic Peptide With Incident Heart Failure and Death.
PubMed 文献 · JAMA Cardiol · 2023-01-01

基于ARIC社区队列9776名基线无临床心衰的成年人,评估第2次与第4次随访间(约6年)NT-proBNP变化与心衰住院及全因死亡的关系;持续≥125 pg/mL者心衰与死亡风险显著升高,NT-proBNP降回<125 pg/mL者风险与始终<125 pg/mL者相近。

要点

  • 6年NT-proBNP持续≥125 pg/mL者心衰风险HR 2.40、死亡风险HR 1.68。
  • NT-proBNP由≥125降至<125 pg/mL者心衰和死亡风险与持续低值者相近。
  • NT-proBNP每增加1个标准差,心衰HR 1.06、死亡HR 1.05。

核心结论

  • 在无临床心衰的社区成年人中,6年NT-proBNP变化反映心衰事件与死亡风险的动态变化,支持系列NT-proBNP检测用于pre-HF风险分层。

研究设计与样本

  • ARIC研究4个美国社区队列,纳入完成第2次与第4次随访(约间隔6年)且有NT-proBNP检测、无现患心衰者共9776人(第2次随访平均年龄57.1岁,女性5523人)。
  • NT-proBNP检测于2011至2013年进行,分析于2021年7月至2022年10月完成。

主要发现

  • 与两次随访NT-proBNP均<125 pg/mL者相比,两次均≥125 pg/mL者心衰风险升高(校正HR 2.40,95%CI 2.00-2.88),死亡风险升高(HR 1.68,95%CI 1.47-1.91)。
  • 第2次随访≥125 pg/mL、第4次随访<125 pg/mL者,心衰(HR 1.01,95%CI 0.71-1.43)和死亡(HR 0.79,95%CI 0.61-1.01)风险与两次均<125 pg/mL者相近。
  • NT-proBNP百分比变化与心衰(每1-SD增加HR 1.06,95%CI 1.02-1.10)和死亡(HR 1.05,95%CI 1.03-1.08)正相关。
  • 收缩压、低密度脂蛋白胆固醇、甘油三酯、体质指数和估算肾小球滤过率的变化与NT-proBNP变化显著相关。

临床怎么用

  • 对pre-HF人群可考虑系列NT-proBNP检测,动态评估心衰与死亡风险。
  • NT-proBNP持续≥125 pg/mL提示风险升高,降至<125 pg/mL者风险接近持续低值人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Most studies, especially in primary prevention patients, have evaluated N-terminal B-type natriuretic peptide (NT-proBNP) at one time point. Evaluation of change in NT-proBNP may improve risk stratification for incident cardiovascular events. OBJECTIVE: To assess the association between change in NT-proBNP and risk for incident heart failure (HF) and death. DESIGN, SETTING, AND PARTICIPANTS: Participants were recruited from 4 US communities enrolled in the Atherosclerosis Risk in Community (ARIC) study. Individuals who attended ARIC visits 2 and 4 (approximately 6 years apart) with measurements of NT-proBNP and without prevalent HF were included. Assays of NT-proBNP were conducted between 2011 and 2013, and analysis took place between July 2021 and October 2022. EXPOSURES: The primary exposure variable was NT-proBNP change between visits 2 and 4, modeled as change categories (<125 pg/mL or ≥125 pg/mL) and as percent change. MAIN OUTCOMES AND MEASURES: The primary outcome measures were incident HF hospitalization and all-cause death. The association between changes in cardiovascular risk factors with change in NT-proBNP was further assessed. RESULTS: A total of 9776 individuals (mean [SD] age, 57.1 [5.7] years at visit 2; 5523 [56.5%] women) were included in the study. Compared with participants with NT-proBNP level less than 125 pg/mL at both visits, participants with NT-proBNP level of 125 pg/mL or higher at both visits had an increase in incident HF (adjusted hazard ratio [HR], 2.40 [95% CI, 2.00-2.88]) and mortality risk (HR, 1.68 [95% CI, 1.47-1.91). Participants with NT-proBNP levels of 125 pg/mL or higher at visit 2 and less than 125 pg/mL at visit 4 had similar risk for HF and death (HR, 1.01 [95% CI, 0.71-1.43]; HR, 0.79 [95% CI, 0.61-1.01]) compared with the group with NT-proBNP levels of less than 125 pg/mL at both visits. The percent change in NT-proBNP was positively associated with HF and death (HR, 1.06 [95% CI, 1.02-1.10]; HR, 1.05 [95% CI, 1.03-1.08] per 1-SD increase, respectively). Change in systolic blood pressure, low-density lipoprotein cholesterol, triglyceride level, body mass index, and estimated glomerular filtration rate were significantly associated with change in NT-proBNP. CONCLUSIONS AND RELEVANCE: In this study, 6-year change in NT-proBNP reflected dynamic change in risk for HF events and death among community-dwelling adults without prevalent clinical HF. These results support the utility of serial NT-proBNP measurements to improve risk stratification of patients with pre-HF.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Jia, Al Rifai, Hoogeveen, et al. Association of Long-term Change in N-Terminal Pro-B-Type Natriuretic Peptide With Incident Heart Failure and Death. JAMA Cardiol. 2023. PMID: 36753229. doi:10.1001/jamacardio.2022.5309

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。